Personalization of External Beam Radiation Therapy in Localised Tumours

Launched by EUROPEAN INSTITUTE OF ONCOLOGY · Jun 24, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how to personalize radiation therapy for patients with early-stage breast or prostate cancer. The goal is to use advanced MRI scans and biological samples taken before treatment to better understand how each patient’s tumor responds to radiation. By doing this, doctors hope to improve the way radiation therapy is planned and delivered, making it more effective and tailored to each individual.

Patients who might be eligible include adults with specific types of breast or prostate cancer that have not spread to other parts of the body. For breast cancer, this means having a common type of tumor in one breast without previous chest radiation or certain other health conditions. For prostate cancer, patients need to have localized disease without spread and be in generally good health. Participants will have MRI scans and some may provide tissue samples through a biopsy before starting radiation. These samples will be studied in the lab to see how they react to radiation, helping doctors better understand the treatment. The trial is currently recruiting patients aged 18 and older, and both men and women may be eligible depending on the cancer type.

Gender

ALL

Eligibility criteria

• Inclusion criteria for prostate patients:
• • Unifocal infiltrating ductal breast carcinoma, non-special histotype
• • clinical stage T1-T2,N0
• • No contraindications to MRI, or metal joint prostheses from knee to shoulder included, or femoral stent.
• • Patients aged \>18 years
• • Good general condition (ECOG 0-2)
• • Expected active treatment (crioablation or surgery or radiotherapy ).
• Exclusion Criteria:
• * Exclusion criteria for prostate patients:
• • Nodule involvement and metastasis (cN1 and/or cM1)
• • Concomitant inflammation of the intestine
• • Significant systemic diseases or ongoing oral anticoagulant therapy
• • Non-compliance of dose constraints in the treatment plan
• • Previous invasive cancer, unless the patient has had no disease for at least 3 years
• • Mental disorders that cannot ensure valid informed consent
• Exclusion criteria for breast patients:
• • Histology other than non-special histotype and non-epithelial tumors (sarcoma, lymphoma)
• • Male sex
• • High-risk mutation carrier patients
• • Bilateral breast cancer
• • synchronous distant metastases
• • Neoadjuvant therapy
• • autoimmune connective tissue diseases
• • previous radiotherapy to the chest
• • Mental disorders that cannot ensure valid informed consent
• • No previous thoracic radiotherapy